DESCRIPTION:

List of positional candidate genes after correcting for multiple testing and controlling the false discovery rate from genome wide association studies (GWAS) retrieved from the NHGRI-EBI Catalog of published genome-wide association studies (http://www.ebi.ac.uk/gwas/). The disease/trait examined in this study, as reported by the authors, was Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer. The EFO term peripheral neuropathy, response to docetaxel, metastatic prostate cancer was annotated to this set after curation by NHGRI-EBI. Intergenic SNPS were mapped to both the upstream and downstream gene. P-value uploaded. This gene set was generated using gwas2gs v. 0.1.8 and the GWAS Catalog v. 1.0.1.

LABEL:

GWAS: peripheral neuropathy, response to docetaxel, metastatic prostate cancer

SCORE TYPE:

P-Value

DATE ADDED:

2017-05-02

DATE UPDATED:

2024-04-25

SPECIES:

AUTHORS:

DL Hertz, K Owzar, S Lessans, C Wing, C Jiang, WK Kelly, J Patel, S Halabi, Y Furukawa, HE Wheeler, AB Sibley, C Lassiter, L Weisman, D Watson, SD Krens, F Mulkey, CL Renn, EJ Small, PG Febbo, I Shterev, DL Kroetz, PN Friedman, JF Mahoney, MA Carducci, MJ Kelley, Y Nakamura, M Kubo, SG Dorsey, ME Dolan, MJ Morris, MJ Ratain, HL McLeod

TITLE:

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.

JOURNAL:

Clinical cancer research : an official journal of the American Association for Cancer Research Oct 2016, Vol 22, pp. 4890-4900

ABSTRACT:

Discovery of SNPs that predict a patient's risk of docetaxel-induced neuropathy would enable treatment individualization to maximize efficacy and avoid unnecessary toxicity. The objectives of this analysis were to discover SNPs associated with docetaxel-induced neuropathy and mechanistically validate these associations in preclinical models of drug-induced neuropathy. PUBMED: 27143689
Find other GeneSets from this publication